What to Expect From HCA Healthcare’s Upcoming Earnings Results?

Oppenheimer analysts provided their outlook on HCA Healthcare, Inc’s (NYSE:HCA) upcoming Q2 earnings, expecting the company to post an adjusted EBITDA of $2.775 billion (vs. Street’s $2.809 billion), adjusted EPS of $3.69 (vs. Street’s $3.70) and revenue of $15 billion (vs. Street’s $60.4 billion).

On June 30, the company pre-announced Q2 results and lowered 2022 guidance due to a muted rebound in non-COVID volumes and persistent labor pressures. Based on the industry backdrop, the analysts believe expectations are fairly muted for Q2. Furthermore, they believe a potential recession could stoke fears around higher bad debt and weaker elective procedures. Nevertheless, the analysts think that the company is attractively valued and remain confident that it will operationally outperform its peers. The analysts maintained their outperform rating and $255 price target.